Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Immunology
Impact-faktor: 1.404 5-jähriger Impact-Faktor: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Druckformat: 1040-8401
ISSN Online: 2162-6472

Volumes:
Volumen 40, 2020 Volumen 39, 2019 Volumen 38, 2018 Volumen 37, 2017 Volumen 36, 2016 Volumen 35, 2015 Volumen 34, 2014 Volumen 33, 2013 Volumen 32, 2012 Volumen 31, 2011 Volumen 30, 2010 Volumen 29, 2009 Volumen 28, 2008 Volumen 27, 2007 Volumen 26, 2006 Volumen 25, 2005 Volumen 24, 2004 Volumen 23, 2003 Volumen 22, 2002 Volumen 21, 2001 Volumen 20, 2000 Volumen 19, 1999 Volumen 18, 1998 Volumen 17, 1997 Volumen 16, 1996 Volumen 15, 1995 Volumen 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v20.i1.20
40 pages

CD4+ T Cells in Adoptive Immunotherapy and the Indirect Mechanism of Tumor Rejection

Peter A. Cohen
Center for Surgery Research, NE6-307, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Liaomin Peng
Center for Surgery Research, FF-50, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195
Gregory E. Plautz
Center for Surgery Research, FF-50, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195
Julian A. Kim
Center for Surgery Research, FF-50, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195
David E. Weng
Center for Surgery Research, FF-50, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195
Suyu Shu
Center for Surgery Research, NE6-307, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA

ABSTRAKT

Tumor-specific CD4+ effector T cells often play a decisive role in immunologic tumor rejection, in some cases without evident co-participation of CD8+ T cells. During such CD4+ T-cell-mediated rejection there is often no delectable direct contact between T cells and tumor cells. Optimally prepared, adoptively transferred CD4+ T cells can reject established tumors with great efficiency even when targeted tumor cells express no MHC Class II molecules, implying that recognition of tumor antigen (Ag) occurs via MHC Class II-expressing host antigen-presenting cells (APC) within the tumor. Because consequent rejection also excludes Ag-specific contact between CD4+ T cells and MHC Class IIneg tumor cells, the most critical CD4+ T-cell-mediated event is likely cytokine release, resulting in an accumulation and activation of accessory cells such as tumoricidal macrophages and lymphokine-activated killer cells. Although such an indirect rejection mechanism may appear antithetical to popular strategies centered on CD8+ cytotoxic T cells (CTL), current evidence suggests that even CD8+ T-cell-mediated recognition/rejection often bypasses direct tumor cell contact and is largely cytokine mediated. While CTL are likely to participate prominently in many models of tumor rejection, indirect mechanisms of recognition/ rejection have the theoretical advantage of remaining operative even when individual tumor cells evade direct contact by down-regulating MHC and/or Ag expression


Articles with similar content:

NK Cells in Therapy of Cancer
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 1-2
Veronika Bachanova, Jeffrey S. Miller
Cross-Presentation of Antigens by Dendritic Cells
Critical Reviews™ in Immunology, Vol.22, 2002, issue 5-6
William R. Heath, Francis R. Carbone, Gabrielle T. Belz
Cytokine Synergy in Antigen-Independent Activation and Priming of Naive CD8+ T Lymphocytes
Critical Reviews™ in Immunology, Vol.29, 2009, issue 3
Julien Gagnon, Stephanie Dubois, Martin V. Richter, Subburaj Ilangumaran, Melissa Forand-Boulerice, Sheela Ramanathan
Immunological Protection Against Mycobacterium tuberculosis Infection
Critical Reviews™ in Immunology, Vol.26, 2006, issue 6
Yasunobu Yoshikai
Autoimmunity and the Immunotherapy of Cancer: Targeting the "Self" to Destroy the "Other"
Critical Reviews™ in Immunology, Vol.20, 2000, issue 6
Nicholas P. Restifo, Willem W. Overwijk